Zealand Pharma may use acquisition option to beef up commercial muscle, CEO says

Should Zealand Pharma choose to exercise its options under its new financing agreement with Oberland Capital, opening up access to USD 200m, efforts to strenghten the firm's commercial business would likely be investigated, says CEO Emmanuel Dulac.

Emmanuel Dulac, CEO at Zealand Pharma | Photo: Stine Bidstrup/ERH

On Tuesday, Zealand Pharma secured a USD 50m option for potential acquisitions of products or companies in a financing agreement with private investment firm Oberland Capital.

However, with clinical trials underway and its goal of having five products on the market in 2025, Zealand Pharma is already well-armed in this business area, CEO at Zealand Pharma Emmanuel Dulac tells MedWatch. Funding from the option, which much be exercised before June 30, 2023, would likely be spent elsewhere.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs